Recap: Lantern Pharma Q4 Earnings
Portfolio Pulse from Benzinga Insights
Lantern Pharma (NASDAQ:LTRN) reported Q4 earnings, beating estimated earnings by 3.0% with an EPS of $-0.39 versus an estimate of $-0.4. However, revenue was unchanged from the same period last year. Following last quarter's earnings beat, the share price increased by 33.0% the next day.
March 18, 2024 | 8:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lantern Pharma reported a Q4 earnings beat with an EPS of $-0.39, surpassing estimates. Despite this, revenue remained flat compared to last year.
Beating earnings estimates typically has a positive impact on a company's stock price, as seen in the previous quarter when LTRN's share price surged by 33% following their earnings beat. However, the flat revenue might temper investor enthusiasm, potentially limiting the upside.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100